TargetMol

TG53

Product Code:
 
TAR-T26265
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26265-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26265-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26265-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
TG53 is a tissue transglutaminase (TG2) and fibronectin (FN) protein-protein interaction inhibitor.
CAS:
946369-04-6
Formula:
C21H22ClN5O2
Molecular Weight:
411.89
Purity:
0.98
SMILES:
COc1ccc(Cl)cc1C(=O)Nc1ccc(Nc2nc(C)cc(n2)N(C)C)cc1

References

1. Yakubov B, Chen L, Belkin AM, Zhang S, Chelladurai B, Zhang ZY, Matei D. Small molecule inhibitors target the tissue transglutaminase and fibronectin interaction. PLoS One. 2014 Feb 20;9(2):e89285. doi: 10.1371/journal.pone.0089285. eCollection 2014. PubMed PMID: 24586660; PubMed Central PMCID: PMC3930694. 2. Herrera VL, Ponce LR, Ruiz-Opazo N. Genome-wide scan for interacting loci affecting human cholesteryl ester transfer protein-induced hypercholesterolemia in transgenic human cholesteryl ester transfer protein F2-intercross rats. J Hypertens. 2007 Aug;25(8):1608-12. PubMed PMID: 17620956. 3. Herrera VL, Shen L, Lopez LV, Didishvili T, Zhang YX, Ruiz-Opazo N. Chlamydia pneumoniae accelerates coronary artery disease progression in transgenic hyperlipidemia-genetic hypertension rat model. Mol Med. 2003 May-Aug;9(5-8):135-42. PubMed PMID: 14571321; PubMed Central PMCID: PMC1430827. 4. Herrera VM, Didishvili T, Lopez LV, Zander K, Traverse S, Gantz D, Herscovitz H, Ruiz-Opazo N. Hypertension exacerbates coronary artery disease in transgenic hyperlipidemic Dahl salt-sensitive hypertensive rats. Mol Med. 2001 Dec;7(12):831-44. PubMed PMID: 11844871; PubMed Central PMCID: PMC1950013.